Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review

Agata Juszczak, Avinash Gupta, Niki Karavitaki, Mark R Middleton, Ashley B Grossman

Research output: Contribution to journalArticlepeer-review

81 Citations (Scopus)


Ipilimumab (Yervoy; Medarex and Bristol-Myers Squibb) is a human MAB against cytotoxic T-lymphocyte antigen 4, which enhances co-stimulation of cytotoxic T-lymphocytes, resulting in their proliferation and an anti-tumour response. It is licensed for the treatment of unresectable or metastatic malignant melanoma, while multiple clinical trials using this medication in the treatment of other malignancies are ongoing. As a clinical response to ipilimumab results from immunostimulation, predictably it generates autoimmunity as well, causing immune-related adverse events in the majority of patients. Of those, endocrinopathies are frequently seen, and in particular, autoimmune lymphocytic hypophysitis with anterior panhypopituitarism has been reported a number of times in North America. We present a case of a male referred to our department with manifestations of anterior panhypopituitarism after his third dose of ipilimumab for metastatic malignant melanoma, and we discuss the management of his case in the light of previous reports. We also review the published literature on the presenting symptoms, time to presentation, investigations, imaging, treatment and follow-up of ipilimumab-induced autoimmune lymphocytic hypophysitis.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalEuropean Journal of Endocrinology
Issue number1
Publication statusPublished - Jul 2012


  • Antibodies, Monoclonal
  • Autoimmune Diseases
  • CTLA-4 Antigen
  • Humans
  • Hypopituitarism
  • Male
  • Melanoma
  • Middle Aged
  • Skin Neoplasms
  • T-Lymphocytes, Cytotoxic


Dive into the research topics of 'Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review'. Together they form a unique fingerprint.

Cite this